Morphic therapeutic announces closing of public offering and full exercise of underwriters' option to purchase additional shares

Waltham, mass., may 05, 2023 (globe newswire) -- morphic holding, inc. (“morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the closing of an underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock. morphic received gross proceeds of approximately $276.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
MORF Ratings Summary
MORF Quant Ranking